TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 405123

Group type: EXPERIMENTAL
Intervention: Synoviorthesis by erbium-169
Number of subjects: 201

Group type: COMPARATOR
Intervention: Intra-articular placebo
Number of subjects: 201

Group type: COMPARATOR
Intervention: Corticotherapy
Number of subjects: 201
Study: 30109456

Group type: EXPERIMENTAL
Intervention: HIV self-test kits announced via text message sent three times
Number of subjects: 2196

Group type: COMPARATOR
Intervention: General HIV testing announced via text message sent three times (enhanced SOC)
Number of subjects: 2196

Group type: COMPARATOR
Intervention: General HIV testing announced via text message sent one time (traditional SOC)
Number of subjects: 2196
Study: 29067906

Group type: EXPERIMENTAL
Intervention: Fresh RBCs stored for ≤ 7 days
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Standard-aged RBCs
Number of subjects: 1211
Study: 24684520

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (8-week treatment as an adjunct to usual psoriasis therapy)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual psoriasis therapy alone (Control group)
Number of subjects: 29
Study: 24423341

Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CD163 mRNA expression
Number of subjects: 69

Group type: COMPARATOR
Intervention: Dietary intervention (very low-calorie diet)
Number of subjects: 69
Study: 23427387

Group type: EXPERIMENTAL
Intervention: Jiutengzhuyu tablets taken orally for 25 days
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intrauterine infusion of 5 mg dexamethasone sodium phosphate, 4000 units of chymotrypsin, 80,000 units of gentamicin sulfate in 20 mL normal saline at 1 mL/min
Number of subjects: 115
Study: 19155999

Group type: EXPERIMENTAL
Intervention: Paclitaxel (100 mg/m(2) d(1), d(8), d(15)) plus gemcitabine (1250 mg/m(2) d(1) and d(8), every 4 weeks) - Arm B
Number of subjects: 228

Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m(2), d(1)) and gemcitabine (1250 mg/m(2), d(1) and d(8), every 3 weeks) - Arm A
Number of subjects: 228
Study: 17637394

Group type: EXPERIMENTAL
Intervention: Model combining parametric Lyman probit with nonparametric decision trees
Number of subjects: 234

Group type: COMPARATOR
Intervention: LNTCP
Number of subjects: 234
Study: 15110616

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ATG-fresenius (group B)
Number of subjects: 40
Study: 11822009

Group type: EXPERIMENTAL
Intervention: Expandable metal stents or ablative therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 0
Study: 9846778

Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum dosage of 3600 mg/d)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 8087332

Group type: EXPERIMENTAL
Intervention: 0.6 ppm NO2 followed by 0.3 ppm O3
Number of subjects: 21

Group type: COMPARATOR
Intervention: Air exposure followed by 0.3 ppm O3
Number of subjects: 21
Study: 29205157

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Thin-strut durable polymer everolimus-eluting stent (DP-EES)
Number of subjects: 1250
Study: 27592206

Group type: EXPERIMENTAL
Intervention: Step-up approach with intention to avoid surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Step-up approach as a bridge to surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 40
Study: 24593836

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supragingival scaling treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 60
Study: 22172433

Group type: EXPERIMENTAL
Intervention: LibiGel (low-dose testosterone gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20823282

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily (arm A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Raltegravir 400 mg plus atazanavir 400 mg once daily (arm B)
Number of subjects: 19
Study: 18434927

Group type: EXPERIMENTAL
Intervention: Facial nerve monitoring with electrodes placed into orbicularis oculi (1.5‐cm spacing; n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Facial nerve monitoring with electrodes placed into orbicularis oris (1.0‐cm spacing; n = 15)
Number of subjects: 30
Study: 16395096

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (2 doses, 6-8 weeks apart)
Number of subjects: 494

Group type: COMPARATOR
Intervention: MMR+V group (1 dose of MMR and 1 dose of varicella, followed by a second dose of MMR at 6-8 weeks later)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (after first dose)
Number of subjects: 494

Group type: COMPARATOR
Intervention: MMR+V group (after first dose)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: MMRV vaccine (after second dose)
Number of subjects: 494

Group type: COMPARATOR
Intervention: MMR+V group (after second dose)
Number of subjects: 494
Study: 12897596

Group type: EXPERIMENTAL
Intervention: Statistical power and sample size in studies published in 1997 in the American and British volumes of the Journal of Bone and Joint Surgery, and in Clinical Orthopaedics and Related Research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized control trials in the journals examined
Number of subjects: 0
Study: 10816184

Group type: EXPERIMENTAL
Intervention: Daily interruption of sedative infusions
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (interruption at clinician's discretion)
Number of subjects: 128
Study: 8622612

Group type: EXPERIMENTAL
Intervention: Intravenous endothelin-1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg) pretreatment before endothelin-1 infusion
Number of subjects: 6
Study: 1595824

Group type: EXPERIMENTAL
Intervention: Elbow orthosis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bilateral hand splints
Number of subjects: 2

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 2
Study: 3883964

Group type: EXPERIMENTAL
Intervention: UV filter on the operating microscope
Number of subjects: 297

Group type: COMPARATOR
Intervention: No UV filter on the operating microscope
Number of subjects: 297
Study: 31728623

Group type: EXPERIMENTAL
Intervention: Post-DOMS protocol in extension
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-DOMS protocol
Number of subjects: 20
Study: 29654204

Group type: EXPERIMENTAL
Intervention: Prasugrel cessation (any type)
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Prasugrel disruption
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Prasugrel cessation (crossover or discontinuation)
Number of subjects: 1830
Study: 26319955

Group type: EXPERIMENTAL
Intervention: Peppermint oil (PO) 3 times daily for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo 3 times daily for 4 weeks
Number of subjects: 72
Study: 25694037

Group type: EXPERIMENTAL
Intervention: MK-7 (180 µg MenaQ7/day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 22869206

Group type: EXPERIMENTAL
Intervention: Citizenship intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 114
Study: 20431383

Group type: EXPERIMENTAL
Intervention: Early BCG vaccination in low-birth-weight babies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early measles vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altered timing of DTP vaccination
Number of subjects: 0
Study: 19719770

Group type: EXPERIMENTAL
Intervention: Volunteer home-visiting support from Home-Start
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case-matched controls (no volunteer support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Those offered but not receiving support
Number of subjects: 0
Study: 15696079

Group type: EXPERIMENTAL
Intervention: Zafirlukast, 80 mg twice daily for 6 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 25
Study: 12854927

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg intravaginally every 3 h for a maximum of 24 h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert (10 mg every 12 h for a maximum of 24 h)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study: 10543411

Group type: EXPERIMENTAL
Intervention: 2 mg glimepiride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 mg glimepiride
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1 mg glibenclamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 24
Study: 8911107

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (CTC) incorporating cyclophosphamide, thiotepa, and carboplatin with autologous PBSC support.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (CTC) with autologous PBSC support.
Number of subjects: 70
Study: 1671188

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 12
Study: 6129380

Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet for 6 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Omnivorous diet for 14 weeks (Control)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Reverted to omnivorous diet after vegetarian diet
Number of subjects: 59
Study: 31298171

Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation therapy (CCRT)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 311
Study: 30131318

Group type: EXPERIMENTAL
Intervention: Blended therapy
Number of subjects: 350

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 350
Study: 26707418

Group type: EXPERIMENTAL
Intervention: 360° ALPI
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medical therapy (Travoprost 0.004%)
Number of subjects: 80
Study: 24754066

Group type: EXPERIMENTAL
Intervention: Adequate eradication therapy during treatment for CHD
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antisecretory therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Treatment for CHD only
Number of subjects: 112
Study: 22422931

Group type: EXPERIMENTAL
Intervention: Simplified Group (SG) - separation of the sympathetic chain at T2 and T3
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional Group (CG) - excision of T2 and T3 ganglia
Number of subjects: 45
Study: 21250572

Group type: EXPERIMENTAL
Intervention: Cerabien ZR (CZR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GC Initial (GCI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lava Ceram (LC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (VO)
Number of subjects: 90
Study: 18999087

Group type: EXPERIMENTAL
Intervention: Health maintenance reminders via PHR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16442886

Group type: EXPERIMENTAL
Intervention: Subgroup analyses in RCTs
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Large RCTs (> 500 patients)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall results (positive/negative) and CONSORT adoption
Number of subjects: 63
Study: 12765426

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg q.i.d. for 28 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11116699

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.5% apraclonidine
Number of subjects: 27
Study: 10169531

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg QID
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Zileuton 600 or 800 mg TID
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Zileuton 600 or 800 mg BID
Number of subjects: 278
Study: 8316882

Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard surgery
Number of subjects: 50
Study: 3323263

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29164421

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus letrozole (2.5 mg/day; continuous)
Number of subjects: 668
Study: 26408375

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with doxycycline 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24556098

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 220

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 220
Study: 22170412

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Meloxicam (10 mg once daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 29
Study: 20159131

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multisensor
Number of subjects: 60
Study: 18627323

Group type: EXPERIMENTAL
Intervention: Contraceptive containing 20 microg ethinylestradiol/75 microg gestodene (Group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Contraceptive containing 30 microg ethinylestradiol/75 microg gestodene (Group B)
Number of subjects: 70
Study: 16080277

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 900 mg tablet (test formulation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gemfibrozil 900 mg tablet (reference formulation)
Number of subjects: 36
Study: 11821720

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nifedipine GITS (30-60 mg)
Number of subjects: 42
Study: 10355007

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish mouthguard (3.0% chlorhexidine varnish)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo varnish mouthguard
Number of subjects: 46
Study: 8543496

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 3125

Group type: COMPARATOR
Intervention: Comparator agents (cephalosporins, imipenem/cilastatin)
Number of subjects: 3125
Study: 1771090

Group type: COMPARATOR
Intervention: 75 mg amitriptyline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline + 3 mg flupentixol
Number of subjects: 34
Study: 7130553

Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31070507

Group type: EXPERIMENTAL
Intervention: Emergency Access Button (EAB) allowing callers to bypass the telephone queue
Number of subjects: 217510

Group type: EXPERIMENTAL
Intervention: EAB users
Number of subjects: 217510

Group type: COMPARATOR
Intervention: EAB non-users (3.3% with EAB option and 1.7% without EAB option)
Number of subjects: 217510

Group type: EXPERIMENTAL
Intervention: EAB use rated by triage professionals
Number of subjects: 217510
Study: 28688622

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg daily for 10 days (n=21)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo 20mg daily for 10 days (n=23)
Number of subjects: 65
Study: 26390517

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100
Study: 24739815

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 40
Study: 22823858

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both CBT and ACT
Number of subjects: 87
Study: 20435692

Group type: EXPERIMENTAL
Intervention: Metformin (BMI > 32 kg/m(2))
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo (BMI > 32 kg/m(2))
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Metformin (BMI < or = 32 kg/m(2))
Number of subjects: 171

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) (BMI < or = 32 kg/m(2))
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Combination of Metformin plus CC (BMI < or = 32 kg/m(2))
Number of subjects: 171
Study: 18043425

Group type: EXPERIMENTAL
Intervention: Plano spectacles with 1 Delta BU, 2 Delta BO, 2 Delta BI prism power
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (plano spectacles)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.5 Delta vertical prism
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.0 Delta base out and 1.0 Delta base in
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Readymade spectacles
Number of subjects: 9
Study: 16237140

Group type: EXPERIMENTAL
Intervention: Protocol B (CT at 90 kV with 100 mL contrast material)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protocol C (CT at 90 kV with 80 mL contrast material)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Protocol A (CT at 120 kV with 100 mL of contrast material)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 90 kV (protocols B and C)
Number of subjects: 40
Study: 12394963

Group type: EXPERIMENTAL
Intervention: Inhaled nitrogen oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 0
Study: 10855800

Group type: EXPERIMENTAL
Intervention: Dedicated, timed, recurring Master's level social work intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, mandated social work services
Number of subjects: 0
Study: 7483486

Group type: EXPERIMENTAL
Intervention: Abbott ELISA
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Murex ELISA
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Ortho ELISA
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: RIBA-2
Number of subjects: 403

Group type: COMPARATOR
Intervention: Probit analysis
Number of subjects: 403
Study: 2262581

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Saline rinse
Number of subjects: 15

Group type: COMPARATOR
Intervention: Commercially available toothpaste and gel products
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stannous fluoride products
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triclosan products
Number of subjects: 15
Study: 6680722

Group type: EXPERIMENTAL
Intervention: 4-min tape of a woman's voice at 80 db SPL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4-min tape of random noise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no stimulus presentation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Random noise
Number of subjects: 30
Study: 31324862

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 0.25 mg/kg
Number of subjects: 65
Study: 28043163

Group type: EXPERIMENTAL
Intervention: Non-Adherence Report (NAR-M)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Medication Adherence Report Scale (MARS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Electronic adherence monitoring
Number of subjects: 84
Study: 27409278

Group type: EXPERIMENTAL
Intervention: Brief training on existing internet-based hearing healthcare (IHHC) websites
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study: 24959775

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 171
Study: 22198441

Group type: EXPERIMENTAL
Intervention: Citalopram plus omega-3 fatty acids (900 mg eicosapentaenoic acid, 200 mg docosahexaenoic acid, 100 mg other omega-3 fatty acids, two 1 g capsules twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Citalopram plus placebo (olive oil, two 1 g capsules per day)
Number of subjects: 42
Study: 19750404

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 10
Study: 20528992

Group type: EXPERIMENTAL
Intervention: Aquacel Ag dressing, changed every 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine, changed daily
Number of subjects: 70
Study: 16286208

Group type: EXPERIMENTAL
Intervention: Headgear (HG)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fränkel function regulator (FR)
Number of subjects: 65
Study: 12369079

Group type: EXPERIMENTAL
Intervention: Drug treatment for capsaicin-induced coughing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin at escalating levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-linear autoregressive model for count data
Number of subjects: 0
Study: 9713448

Group type: COMPARATOR
Intervention: L‐NAME 54 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: L‐NAME 170 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 28
Study: 7868876

Group type: COMPARATOR
Intervention: Placebo (1.5 ml/min saline) during exercise test
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Naloxone (9.5 micrograms/kg per min) during exercise test
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rest (no intervention)
Number of subjects: 18